Login / Signup
A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients without diabetes.
Ellen F Carney
Published in:
Nature reviews. Nephrology (2024)
Keyphrases
</>
end stage renal disease
ejection fraction
type diabetes
newly diagnosed
chronic kidney disease
cardiovascular disease
clinical trial
peritoneal dialysis
prognostic factors
phase iii
adipose tissue
randomized controlled trial
phase ii
patient reported outcomes